Ask AI
SENTRY
SENTRY: Phase III Study of Selinexor + Ruxolitinib in Patients With JAK Inhibitor–Naive Myelofibrosis

Released: July 02, 2026

Activity

Progress
1
Course Completed
Activity Information

Released: July 02, 2026